15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Caribou Biosciences Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $11.00 to $11.00, so the covering firms are broadly aligned. The average target of $11.00 sits 643% above the current $1.48. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.32 next quarter toward $-1.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Caribou Biosciences Inc.
As of Jul, 4 of 4 firms rate CRBU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRBU EPS & revenue forecast
EPS · NEXT QUARTER
$-0.32
Range $-0.35 – $-0.29 · 3 analysts
Next period, 3 analysts expect Caribou Biosciences Inc to earn $-0.32 a share (range $-0.35 – $-0.29), versus — a year earlier. Full-year consensus is $-1.25, growing to $-1.40 the year after.
REVENUE · NEXT QUARTER
$2.2M
Range $0 – $2.9M · 3 analysts · -1% YoY
Revenue is expected to reach $2.2M (range $0 – $2.9M), -0.8% year-over-year. Full-year consensus is $25.7M, rising to $30.1M next year.
Top analysts covering Caribou Biosciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRBU.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$11.00+643.2% to target
Overall win rate
38%
+ Follow
#2
Asthika Goonewardene
Truist Securities
Buy
$7.00+373.0% to target
Coverage
—
+ Follow
#3
JM
Jonathan Miller
Evercore ISI
Buy
$13.00+778.4% to target
Coverage
—
+ Follow
#4
WM
William Maughan
Clear Street
Buy
$13.00+778.4% to target
Coverage
—
+ Follow
CRBU stock forecast FAQ
What is CRBU's average 12-month price target?+
The 1 analysts with a live target average $11.00 for Caribou Biosciences Inc over the next 12 months, ranging from a $11.00 high to a $11.00 low.
Is CRBU stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover CRBU?+
4 analysts have an active rating on Caribou Biosciences Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRBU?+
Among analysts who currently cover CRBU, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Buy with a $11.00 target.
What is Caribou Biosciences Inc's projected EPS for next quarter?+
The consensus estimate is $-0.32 per share (range $-0.35 – $-0.29) across 3 analysts. Full-year EPS is projected at $-1.25, rising to $-1.40 the following year.
How much revenue is Caribou Biosciences Inc expected to report next quarter?+
Consensus revenue is $2.2M (range $0 – $2.9M). Full-year revenue is projected at $25.7M, growing to $30.1M next year.
Have analysts been upgrading or downgrading CRBU lately?+
As of Jul, 4 of 4 firms rate CRBU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRBU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
